Cycloset

DRUG3 trials

Sponsors

VeroScience, The University of Texas Health Science Center at San Antonio, Eastern Virginia Medical School

Conditions

Diabetic Autonomic NeuropathyType 2 DiabetesType 2 Diabetes Mellitus

Phase 3

Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes

CompletedNCT00377676

VeroScienceType 2 Diabetes Mellitus

Start: 2004-07-31End: 2007-01-31Updated: 2016-06-10

Phase 4

Effect of Cycloset on Glycemic Control When Added to Glucagon-like Peptide 1 (GLP-1) Analogue Therapy

CompletedNCT02299050

The University of Texas Health Science Center at San AntonioType 2 Diabetes

Start: 2014-06-30End: 2018-04-30Updated: 2019-06-21

Bromocriptine-QR Therapy on Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects

CompletedNCT02682901

Eastern Virginia Medical SchoolDiabetic Autonomic Neuropathy

Start: 2015-10-05End: 2018-11-15Updated: 2021-12-10

Related Papers

Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin

Postgraduate Medicine2017-04-0525 citations

Impact of bromocriptine-QR therapy on cardiovascular outcomes in type 2 diabetes mellitus subjects on metformin

Postgraduate Medicine2016-09-3020 citations

Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus.

2015-04-2829 citations

How many unpublished studies? ClinicalTrials.gov (n = 2614 studies): diabetes | Closed Studies | Interventional Studies | Phase 3, 4 | Search Date: Oct 27, 2014

Figshare2014-01-01

Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects.

2012-10-2571 citations

Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes.

2010-03-23137 citations

A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset or placebo.

2007-06-2542 citations